Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma

Athanasios B.T. Fassas, K. R. Desikan, David Siegel, Thomas A. Golper, Nikhil C. Munshi, Bart Barlogie, Guido Tricot

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management of this disease, it is conceivable that clinicians will encounter this complication more frequently. A retrospective analysis of > 800 patients with multiple myeloma treated at the University of Arkansas identified nine patients who developed a marked tumour lysis syndrome following intermediate- or high-dose chemotherapy. Evaluation of disease characteristics revealed association with high tumour mass, high proliferative activity, increased lactic dehydrogenase levels, plasmablastic morphology, and unfavourable cytogenetic abnormalities. Recognition of multiple myeloma patients at high risk for the development of tumour lysis syndrome and prompt intervention are required especially in the presence of abnormal baseline renal function frequently complicating the clinical course of these patients.

Original languageEnglish
Pages (from-to)938-941
Number of pages4
JournalBritish Journal of Haematology
Volume105
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Keywords

  • High-risk features
  • Multiple myeloma
  • Renal function
  • Tumour lysis syndrome

Fingerprint

Dive into the research topics of 'Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this